Oma Agbai is a Dermatology physician affiliated with University of California, Davis. OpenAlex indexes 28 publications with 1,265 citations (h-index 14); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3301 C St
Sacramento, CA 958163300
Telephone
916-734-6371Registry record last updated 2 Dec 2014.
Clinical trials
- Intralesional Cyclosporine for Alopecia Areata
Sponsor: University of California, Davis
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- UCB, Inc.Program year20251 payment
- Blueprint Medicines CorporationProgram year20251 payment
- ABBVIE INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
29.8%Tetracycline-class Drug15.2%Doxycycline Hyclate92%Doxycycline Monohydrate8%Part D<11 patientsAzole Antifungal9.9%Ketoconazole100%Part D≥42 patients+ 1 more class in this area
Sensory organs
22.8%Corticosteroid22.8%Clobetasol Propionate68%Hydrocortisone22%Betamethasone Dipropionate9%Part D<11 patientsCancer & immunology
19.9%Nucleoside Metabolic Inhibitor5.9%Fluorouracil100%Part D≥45 patientsCalcineurin inhibitor4.8%Tacrolimus100%Part D≥22 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Lichen planus pigmentosus and erythema dyschromicum perstans: demographic and clinical characteristics in a diverse US cohort
Archives of Dermatological Research
2026 - 63209 Demographic and Clinical Characteristics of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans in an Ethnically Diverse US Population: A Retrospective Study
Journal of the American Academy of Dermatology
2025 - 0170 The impact of age on healing times in radiation dermatitis
Journal of Investigative Dermatology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Ezra Amsterdam, MD
University of California, Davis
Michael Rogawski, MD
University of California, Davis
Christopher Bowlus, MD
University of California, Davis
Emanual Maverakis, MD
University of California, Davis
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”